Understanding the R&D landscape

402 views

Published on

The Power of Vaccines: ‘getting to zero’ for HIV and TB was an event hosted by the TB/HIV and Prevention Working Groups of the UK Consortium on AIDS and International Development. The meeting was sponsored by Pamela Nash MP and held on Friday, 18th May 2012, in Portcullis House, Westminster. Read more at http://storify.com/PamojaUK/the-power-of-vaccines

http://www.pamoja.uk.com

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
402
On SlideShare
0
From Embeds
0
Number of Embeds
25
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Understanding the R&D landscape

  1. 1. The Power of Vaccines: ‘getting to zero’ for HIV and TB Understanding the R&D funding landscapeRoni LiyanageSenior Policy Analystrliyanage@policycures.org
  2. 2. Outline• About Policy Cures• About G-FINDER• Neglected disease R&D funding• Vaccine R&D funding• HIV & TB vaccine funding• Key messages
  3. 3. About Policy CuresInnovative ideas andaccurate analysis toaccelerate developmentand uptake of new drugs,vaccines, diagnostics andother products forneglected diseases of thedeveloping world
  4. 4. About G-FINDER• An annual funding survey (2007, 2008, 2009, 2010) – 31 neglected diseases – 134 product areas – All R&D stages• Over 8,000 entries per year – Data from 54 countries <INSERT PICTURE> – Data from 240 organisations• Funded by the Bill & Melinda Gates Foundation WHO/MALI
  5. 5. Neglected Disease R&D Funding
  6. 6. Total Neglected Disease R&D funding $3,500Millions $3,000 $2,500 $3,063 $2,000 million $1,500 invested in neglected disease R&D in 2010 $1,000 $500 ↓$109m (-3.5%) $0 2007 2008 2009 2010
  7. 7. HIV & TB R&D funding $1,200 MillionsHIV/AIDS TB $1,000 $800 $600 HIV$1.07 TB $575.4BILLION $400 MILLIONTotal spend on Total spend on TB R&DHIV/AIDS R&D in 2010 in 2010 $20035% 18.8%of Global ND R&D $- of Global ND R&Dfunding 2007 2008 2009 2010 funding
  8. 8. Vaccine R&D Funding
  9. 9. Vaccine R&D funding $1,400Millions $1,200 62% Public funding $1,000 $800 $600 20% $400 Industry funding $200 $0 2007 2008 2009 2010 17% Public funding Industry funding Philanthropic funding Philanthropic funding
  10. 10. Vaccine R&D funding Bacterial Other 4% Pneumonia & Meningitis 7% Diarrhoeal diseases 7% Malaria 8%HIV/AIDS 55% TB 9% Dengue 10%
  11. 11. Top funders of neglected disease vaccine R&D, 2010 1 NIH $509m 2 Pharmaceutical Industry $223m 3 Bill & Melinda Gates Foundation $176m 4 US Department of Defense (DOD) $43m 5 US Agency for International Development (USAID) $33m 6 UK Department for International Development (DFID) $30m 7 European Commission: Research Directorate-General $27m
  12. 12. HIV & TB Vaccine R&D Funding
  13. 13. HIV & TB Vaccine R&D funding 2007-2010 $700 MillionsHIV/AIDS TB $600 $500 $400 HIV$589.9 $300 TB $81.9million $200 MILLIONTotal spend on HIV Total spend on TBVaccine R&D in 2010 $100 Vaccine R&D in 2010 $- 2007 2008 2009 2010
  14. 14. HIV Vaccine R&D funding – by funder type 2010 IndustryPhilanthropic funding funding 2% Top funders HIV Vaccine R&D, 2010 12% 1 US NIH $414m 2 Bill & Melinda Gates $65m Foundation 3 USAID $27m 4 US DoD $25m 5 Industry $21m 6 UK DFID $14m Public 7 European Commission $10m funding 86% 8 The Wellcome Trust $4m
  15. 15. TB Vaccine R&D funding – by funder type, 2010 Other Industry 2% Top funders TB Vaccine R&D, 2010 funding 1 Bill & Melinda Gates Foundation $30m 9% Public funding 49% 2 Industry $17m 3 US NIH $15m 4 UK DFID $10m 5 Health Protection Agency $4m 6 European Commission $4mPhilanthropic funding 40%
  16. 16. Science & Technology Vs Aid funding90% of public funding for HIV vaccine R&D came from Science and Technology funding agencies in 201066% of public funding for TB vaccine R&D came from Science and Technology funding agencies in 2010
  17. 17. European public funding of HIV Vaccine R&D $70Millions $60 ↓$15.8m (-29%) in 2010 Norway $50 Switzerland France $40 Sweden Denmark $16.7m (-22%) in 2010 $30 From UK Ireland Netherlands $20 European Commission UK $10 $10.8m (-36%) in 2010 $- From EC 2007 2008 2009 2010
  18. 18. European public funding of TB Vaccine R&D $35Millions $30 ↓$5.9m (-20%) in 2010 $25 Spain Sweden $20 Denmark Switzerland $14.3m (up 21%) in 2010 $15 From UK Netherlands European Commission $10 UK $5 $4.0m (-45%) in 2010 From EC $- 2007 2008 2009 2010
  19. 19. The HIV and TB vaccine portfolios302520 Preclinical Several products moving15 Phase I into expensive late-stage Phase II clinical trials10 Phase III 5 0 HIV Vaccines TB Vaccine
  20. 20. Key messages
  21. 21. Vaccine R&D funding for neglected diseases • Funding is highly concentrated • Mostly comes from: • US funders • Public sector • Science and technology budgets • Funding cuts at a time when several promising products are entering late stage development
  22. 22. Vaccine R&D funding for neglected diseases- R&D pipelines need reliable long-term funding- Financial pressures mean smarter funding will be needed: - Outcome driven and flexible - Aligned with product and portfolio developments - Coordinated - Targeted to deliver the highest health impact
  23. 23. It took a long time and a lot of effort to restartneglected disease vaccine R&D but it is underthreat – The time to act is NOW

×